High plasma efavirenz level and CYP2B6*6 are associated with efavirenz-based HAART-induced liver injury in the treatment of naïve HIV patients from Ethiopia: a prospective cohort study (Q56829831)

From Wikidata

Jump to navigation Jump to search

article

Language	Label	Description	Also known as
English	High plasma efavirenz level and CYP2B6*6 are associated with efavirenz-based HAART-induced liver injury in the treatment of naïve HIV patients from Ethiopia: a prospective cohort study	article

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21862974%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

High plasma efavirenz level and CYP2B6*6 are associated with efavirenz-based HAART-induced liver injury in the treatment of naïve HIV patients from Ethiopia: a prospective cohort study (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21862974%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

0 references

0 references

1 reference

based on heuristic

inferred from title

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21862974%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21862974%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

Walter E Haefeli

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21862974%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

Jürgen Burhenne

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21862974%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

12

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21862974%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

author name string

W Amogne

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21862974%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

A Habtewold

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21862974%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

N Ueda

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21862974%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

A Suda

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21862974%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

A Worku

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21862974%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

G Aderaye

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21862974%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

L Lindquist

11

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21862974%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

publication date

23 August 2011

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21862974%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

The Pharmacogenomics Journal

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21862974%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

12

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21862974%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21862974%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

499-506

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21862974%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

https://scigraph.springernature.com/pub.10.1038/tpj.2011.34

0 references

Antiretroviral therapy-induced liver alterations

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2011.34

21 January 2018

Grade 4 Events Are as Important as AIDS Events in the Era of HAART

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2011.34

21 January 2018

Antiretroviral hepatotoxicity in human immunodeficiency virus-infected patients

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2011.34

21 January 2018

Hepatotoxicity in an African antiretroviral therapy cohort: the effect of tuberculosis and hepatitis B.

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2011.34

21 January 2018

Toxicity of non-nucleoside analogue reverse transcriptase inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2011.34

21 January 2018

Hepatotoxicity of antiretrovirals: incidence, mechanisms and management

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2011.34

21 January 2018

Hepatotoxicity associated with protease inhibitor-based antiretroviral regimens with or without concurrent ritonavir

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2011.34

21 January 2018

Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2011.34

21 January 2018

Incidence of liver injury after beginning antiretroviral therapy with efavirenz or nevirapine

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2011.34

21 January 2018

Impact of CYP2B6 polymorphism on hepatic efavirenz metabolism in vitro.

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2011.34

21 January 2018

CYP2B6, CYP2A6 and UGT2B7 genetic polymorphisms are predictors of efavirenz mid-dose concentration in HIV-infected patients

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2011.34

21 January 2018

A novel polymorphism in ABCB1 gene, CYP2B6*6 and sex predict single-dose efavirenz population pharmacokinetics in Ugandans

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2011.34

21 January 2018

Influence of host genetic factors on efavirenz plasma and intracellular pharmacokinetics in HIV-1-infected patients

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2011.34

21 January 2018

Interpatient variability in the pharmacokinetics of the HIV non-nucleoside reverse transcriptase inhibitor efavirenz: the effect of gender, race, and CYP2B6 polymorphism

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2011.34

21 January 2018

Efavirenz plasma concentrations and cytochrome 2B6 polymorphisms

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2011.34

21 January 2018

Effect of CYP2B6, ABCB1, and CYP3A5 polymorphisms on efavirenz pharmacokinetics and treatment response: an AIDS Clinical Trials Group study

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2011.34

21 January 2018

Haplotype structure of CYP2B6 and association with plasma efavirenz concentrations in a Chilean HIV cohort

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2011.34

21 January 2018

Efavirenz-induced acute eosinophilic hepatitis

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2011.34

21 January 2018

Antiretroviral therapy using zidovudine, lamivudine, and efavirenz in South Africa: tolerability and clinical events

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2011.34

21 January 2018

Severe hepatotoxicity associated with nevirapine use in HIV-infected subjects

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2011.34

21 January 2018

Low frequency of liver enzyme elevation in HIV-infected patients attending a large urban treatment centre in Uganda

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2011.34

21 January 2018

Long-term efavirenz autoinduction and its effect on plasma exposure in HIV patients

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2011.34

21 January 2018

Criteria of drug-induced liver disorders. Report of an international consensus meeting

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2011.34

21 January 2018

Incidence and risk factors for liver enzyme elevation during highly active antiretroviral therapy in HIV-HCV co-infected patients: results from the Italian EPOKA-MASTER Cohort

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2011.34

21 January 2018

Predictors of antiretroviral-related hepatotoxicity in the adult AIDS Clinical Trial Group (1989-1999).

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2011.34

21 January 2018

Hepatotoxicity of nucleoside reverse transcriptase inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2011.34

21 January 2018

Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2011.34

21 January 2018

Presence of the CYP2B6 516G> T polymorphism, increased plasma Efavirenz concentrations and early neuropsychiatric side effects in South African HIV-infected patients

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2011.34

21 January 2018

Enhanced oxidative stress and increased mitochondrial mass during efavirenz-induced apoptosis in human hepatic cells

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2011.34

21 January 2018

Fulminant hepatic failure after the start of an efavirenz-based HAART regimen in a treatment-naive female AIDS patient without hepatitis virus co-infection

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2011.34

21 January 2018

A paediatric case of acute liver failure associated with efavirenz-based highly active antiretroviral therapy and effective use of raltegravir in combination antiretroviral treatment after liver transplantation

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2011.34

21 January 2018

The convergence of therapeutic drug monitoring and pharmacogenetic testing to optimize efavirenz therapy

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2011.34

21 January 2018

Sex and CYP3A5 genotype influence total CYP3A activity: high CYP3A activity and a unique distribution of CYP3A5 variant alleles in Ethiopians

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2011.34

21 January 2018

Identifiers

10.1038/TPJ.2011.34

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21862974%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21862974%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q56829831&oldid=1476007925"